contact us

Use the form on the right to contact us.

You can edit the text in this area, and change where the contact form on the right submits to, by entering edit mode using the modes on the bottom right.

           

123 Street Avenue, City Town, 99999

(123) 555-6789

email@address.com

 

You can set your address, phone number, email and site description in the settings tab.
Link to read me page with more information.

Johnson & Johnson (Animas) Exits Insulin Pump Business

Arden's Day Blog

Arden's Day is a type I diabetes care giver blog written by author Scott Benner. Scott has been a stay-at-home dad since 2000, he is the author of the award winning parenting memoir, 'Life Is Short, Laundry Is Eternal'. Arden's Day is an honest and transparent look at life with diabetes - since 2007.

type I diabetes, parent of type I child, diabetes Blog, OmniPod, DexCom, insulin pump, CGM, continuous glucose monitor, Arden, Arden's Day, Scott Benner, JDRF, diabetes, juvenile diabetes, daddy blog, blog, stay at home parent, DOC, twitter, Facebook, @ardensday, 504 plan, Life Is Short, Laundry Is Eternal, Dexcom SHARE, 生命是短暂的,洗衣是永恒的, Shēngmìng shì duǎnzàn de, xǐyī shì yǒnghéng de

Johnson & Johnson (Animas) Exits Insulin Pump Business

Scott Benner

Ping, Poof, Pow!!!

From Reuters - Johnson & Johnson’s diabetes care unit, which makes insulin pumps, said on Thursday it would shut its business in United States and Canada amid increased competition and after failing to find a buyer.

The entire story is here on Reuters.

More from MarketWatch

1.1.2.1_Ping.jpg

Johnson & Johnson's Animas Corp. said Thursday it plans to close operations and exit the insulin pump business. The company will discontinue the manufacturing and sale of its Animas, Vibe and OneTouch Ping insulin pumps. Animas said Medtronic PLC MDT, +1.30% will help facilitate a transition for the 90,000 patients who use Animas pumps, and who will be offered the option to transfer to a Medtronic pump. Animas employs 410 people around the world. The move comes as part of J&J's strategic review announced in January, in which it is continuing to evaluate options for LifeScan, a blood glucose monitoring company with the OneTouch brand of products. J&J's stock was inactive in premarket trade. It has slipped 0.6% over the past three months, while the SPDR Health Care Select Sector ETF XLV, -0.10% has gained 3.9% and the S&P 500 SPX, +0.50% has advanced 4.3%.